Recent BHVN News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 08:18:10 PM
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 10/02/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/01/2024 08:06:51 PM
- Biohaven Announces Pricing of $250 Million Public Offering of Common Shares • PR Newswire (US) • 10/01/2024 10:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/30/2024 09:29:09 PM
- Biohaven Announces Proposed Public Offering of Common Shares • PR Newswire (US) • 09/30/2024 08:05:00 PM
- Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine • PR Newswire (US) • 09/30/2024 11:30:00 AM
- Visa Faces Monopoly Lawsuit; Meta Introduces Celebrity Voices for Chatbot; Stellantis on the Hunt for New CEO • IH Market News • 09/24/2024 10:15:50 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 01:11:53 PM
- Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) • PR Newswire (US) • 09/23/2024 11:30:00 AM
- Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia • PR Newswire (US) • 09/20/2024 11:09:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:35:34 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 08/16/2024 08:31:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:25:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/16/2024 08:21:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:06:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:17:54 PM
- Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments • PR Newswire (US) • 08/08/2024 08:05:00 PM
- Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day • PR Newswire (US) • 05/29/2024 11:30:00 AM
- Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors • PR Newswire (US) • 05/29/2024 11:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:42:44 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 05/17/2024 08:41:07 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/09/2024 08:16:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:14:14 PM
- Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments • PR Newswire (US) • 05/09/2024 08:05:00 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM